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examinedtimereleasechafacfefisticaof the carnerandof the inoorporatsd
drugs.M Twenty7 mmlongcoatedmetallicstentewereimmersedin
a constantflow of humanplasmaat 3PC understerileConditions.Weight,
aPTT,collageninducedthrombecyteaggregationandit’smaximumgradient





10 min 1 h 6 h 12 h 24 h 4S h 4 days 6 days 16 days 30 days
PEG-Hirudin(%) 5.3 9.4 26.4 33.5 39.4 41.6 47.6 52.4 52.6 52.8
PG12(%) 0.9 2.1 3,4 3.8 4.4 5.0 7.1 9.4 11.2 11.8
While providingan effectivebeat antithromboticeffect,the contentof
PG12(2 pg) and PEG-Hiwdin(10 wg) in the coatingof a 7 mm metallic
stentis by a faotorof Id belowthe dosageneededfor a syatemiceffect.
Otherstudieswitha humanstaeemodelhaveshownthatthe coatingwith
PEG-HirudinandIloproetin combinationhasa synergisticeffectwithregard
to antiooegulation.Investigationof markersof aotivatadcoagulationsuch
asTATIll and FI-2 suppotithesefindinga.C WhilePEG-Hirudin
hasa fast initialrelease,PG12releasesmoregradually.Bothdtugsexhibit
a Ioealantithromboticeffectfor at least~ daysat concentrationsfar below
thesyetemicdose.
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Plateletsare involvedin the pathophysiologyof acuteandsubacutethmm-
boticocclusionsof atentsin coronaryarteries.In an in vitromodelof atent
thombasiswe investigatedtheexpressionof activationdependentglycopm-
teina(GP)onplateletsbyflowcytometry.A4atfrod:Coronarystente(eachn =
7) wereplacedInoneof two parallelsilicontubingswithcirculatingcitrated
plateletrichplasma(PRP)to measure1.)plateletaofivation(PA)vs control
withoutstent 2.) influenoeof stent lengthon PA3.) influenceof heparin
ooatingon PAand4.) timeuntilstentthrombosis,(TST).Afterracelcifieation
aiiquotaof PRPweretakenover’10 min in 2 min intervals.Bloodsamples
were immediatelyfixadand stabilized.For flow cytometricanalysismono-
clinal antibedieaCD41a(GPllb4111a),CD42b(GPlb),CD62P(P-selectin)end
CDS3(GP53)wereused.
R Within2 minafterstartof oirculaIion,the expressionof CD62P
and CD63increasedin the tubingsystemwith the stent.Over10 min PA
progressivelyincreased.Longerstentsladto morePAthanshorterstente.
Heparfncoatinghad no influenceon PA,but prolongadTST.Resultaare
expressedasmeanchannelfluorescenceintenaity(MCFI).
Control t5 mm 25 mm Hsparincoated Uncoated
CD620 35.6& 14.1 45.2 & 12.0 56.2& 17.3 52.5& 12.7 50.3 * 11.7
CD62 30.7+ 7.9 39.7+ 9.0 49.6+ 11.5 30.2 * 3.2. 29.4 * 3.1
TST(min) 20.0+ 4.4 16.6+ 3.8 12.2 *4.6 21.5 * 5.3
MCFI:15mmva25mmp < 0.005;15mmvscontrolps 0.005;25mmvs
oontmlp <0.0001,heperincoatedvsunmatedp e n.s.TST:heparincoated
vsuncoatadp <0.001, 15mmvs25mmp <0.05,15 mmvscontrolp e 0.01,
25 mmvs controlp -=0.0001.CD41aandCD42bdid not showsignificant
changes.C In our in vitromcdelthere is stentinducedPA.This
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plateletdepositiona PTCAandstenting a porcinec m
M Animals(n= 12)werepretreatedwithASA(650mg)andgiven
heparinto achievean ACT >300 seconds.After intraarterialnitroglycerin
administration,on-lineQCAmeasurementswereobtainedin eachcorone~
attery.Platelets(PLT)werelabeledusingChromium-51and reinfusedinto
the animal.PTCAand metalstentimplantationswere performedaiminga
balloonto arteryratio (BAR)1.1–1.2:1.Animalswereeuthanizedat 1 and
24 hours.Theheartswareperfusedin vivoandthe atentandPTCAarterial
segmentewereharvestadforgammacounting.
R are summarizedbelow:
PLT x 1071cm2 PTCA (n =22) Stent (n = 20) P
1 hour 3.15 * 3.17 1.34 + 1.69 0,0s
24 hour 0.70 * 1,17* 4.36 + 1.62t 0.002
Means + SD; Mann Whitney.*p = 0,06 vs 1 h, tp = 0.001 vs 1 h
C Onehouraftermetallicstentimplantation,PLTdeposition
doesnotappearto beincreasedcomparedto PTCA.However,at 24 hours,
stenteareaseooiatedwithgreaterPLTdeposition.Thus,between1 and24
hoursa significantPLTaccumulationoccurawithstentsbut notwith PTCA.
Thia may have impatant clinical implioetionswhen trying to reducePLT
depositionafterpercutaneousrevascularizationprocedures.
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Previous studies have shownthat antiplateletherapyalonecaneffectively
preventsubacutestentthrombosis(SST)afferoptimizedsterrtimplantation.
However,it iaunknownwhetherticlopidinecombinedwithaspirinissuperfor
to aspirinalone in preventingSST.Fmm March 1993 to July 1995601
consecutivepatients(pts)assignedto receiveeitheraspirinalone325 mg
eachday(ASA,264pts,346lesions)or a combinationof ticlopidine250mg
twotimesa dayandaspirin325 mg a day(TIC-ASA,537pts,737 lesions)
aftera successfulstent insertion,in mostaccomplishedwith intravascular
ultrasoundguidance,wereretrospeetivelyevaluated.At one monthfollow-
UPbetweenthe ASAand TIC-ASAgroupsthere was no differencein the
rateof SST(1.9°Avs 1.3%,p = 0.5)andcumulativemajoradverseClinical
events(myoe$rdialinfarction,death,repeatintervention,emergencybypaee
surgery)(1.9%vs 2.0%,p = 1). Althoughtheseresultsindicatethat there
is nosignificantgainin clinicalefficacybycombiningticlopidineandaapirin
therapy,it ia notewortythat in the patientswho aufferadSST in the ASA
group,comparedwiththepatientswithSSTinthe TIC-ASAgmup,therewas
a trendfora lowernumberof the“classical”riskfactorsfor atentthrombosis
(2.6+ 1.5vs4.0+ 1.4p= 0.14),withabsenceof fillingdefectsindicativeof
thrombus,noTIMIflow <3, nobailoutstentproceduresdone,andonlyone
caseof LADs suggestingthataspirinalonecouldbe lesspmtaotive
thanthe combinedantiplateletregimenin preventingSST.C At
onemonthclinicalfollow-upSSTandotheradversemajorclinioeloutcomea
werenotsignificantlydifferentbetweentheASAandTIC-ASAgroups.These
resultesupportthe efficacyof aspirinalonein preventingstentthrombosis.
However,untiltheresultsof a largerandomizedtrialwill beknown,it aeems
reasonableto raoommendaspirinmono-therapyto thoaepatientsthat after
optimalstentimplantationhaveno morethan2 of the “claasicel”riskfactors
forstentthrombosis.
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B The mechanismsof atent thrombosis(ST) are inmmpletely
understood.Wetestedthehypothesisthatthreegeneralfactorswhichaffect
intravascularthrombosis:Ioealsurface,rheology,and aystemiccoagulation
statua,alsomodulatestentthrombosis.M R E o
